To evaluate the systemic efficacy of delivering the antibody hPD-1scFv to the TME with YST-OVH in immunocompetent and humanized PD-1 mouse models, we established an orthotopic tumor model and a bilateral flank tumor model in immunocompetent PD-1-HU mice. This evidence concerns the gene PDCD1 and neoplasm.